Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Rhea-AI Summary

Qualigen Therapeutics (NASDAQ: QLGN) will rebrand as AIxCrypto after its stockholder meeting on November 12, 2025. The company announced a Web3 and crypto asset strategic roadmap that includes a public beta launch of the BesTrade DeAI Agent by the end of November and release of an EAI RWA Utility Token Whitepaper.

AIxCrypto set three 2025 targets: grow the C10 Treasury to $50 million AUM, expand global user growth for BesTrade DeAI Agent, and list crypto ecosystem tokens supported by C10 stablecoin and EAI+Crypto RWA bridge products. As of October 17, 2025, the C10 Treasury completed $12 million in crypto asset allocations. The company is majority owned by Faraday Future Intelligent Electric (NASDAQ: FFAI).

Positive

• Rebrand to AIxCrypto timed for Nov 12, 2025
• Public beta of BesTrade DeAI Agent scheduled by end of November 2025
• C10 Treasury already completed $12 million in crypto allocations (Oct 17, 2025)

Negative

• C10 Treasury at $12M versus a $50M year-end AUM target
• Multiple product launches and listings targeted before year-end 2025, creating condensed execution timeline

Insights

Corporate Strategy Analyst

Rebrand and roadmap set explicit product and AUM targets but rely on future execution and approvals.

The company will change its name to AIxCrypto after the November 12, 2025 stockholder meeting and lists three clear 2025 goals: grow the C10 Treasury to $50 Million AUM, launch the BesTrade DeAI Agent public beta by end of November, and publish an EAI RWA Utility Token whitepaper. These are concrete corporate actions that reframe the firm from its prior identity toward Web3 and crypto products.

Execution risk centers on meeting the stated timelines and on converting product launches into measurable adoption; the release cites $12 million in crypto allocations to the C10 Treasury as of October 17, which is a verifiable intermediate figure but materially below the stated year‑end target. Watch the November 12, 2025 meeting outcome, the BesTrade beta launch timing at the end of November, and any regulatory or exchange listings tied to token launches.

Crypto Product Analyst

Product roadmap mixes a beta trading agent, a token whitepaper, and a treasury target; adoption and exchange support will determine impact.

The BesTrade DeAI Agent is described as a Meta Exchange aiming to optimize transaction pathways and returns; the company plans a global user growth campaign after the public beta. The roadmap also includes an EAI RWA Utility Token whitepaper and potential C10 stablecoin, plus plans to list ecosystem tokens on leading exchanges.

Key dependencies include successful beta performance, user-growth conversion, and exchange acceptance for any tokens. Concrete near-term monitors are the BesTrade public beta by end‑of‑November and publication of the EAI whitepaper; these items will provide the first measurable signals of product viability within the timeframe stated for 2025.

Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or the “Company”), a publicly-traded technology company majority owned by Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future” or “FF”), today announced that it will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025.

AIxCrypto’s Strategic Roadmap

QLGN (soon to be AIxCrypto) has launched its new Web3 and crypto asset business initiatives. Following its targeted rebranding on November 12, the Company will launch the public beta of its BesTrade DeAI Agent by the end of November and release its EAI RWA Utility Token Whitepaper.

By the end of 2025, AIxCrypto aims to achieve three major milestones:

1. Expand the C10 Treasury to $50 Million AUM

Strengthen its role as the core reserve asset of the Web3 ecosystem through key products such as C10 Treasury and C10 Index — serving as the first engine of the Crypto Flywheel - as of October 17, QLGN’s C10 Treasury completed $12 million in crypto asset allocations.

2. Accelerate Global Growth of the BesTrade DeAI Agent

As the Company’s flagship product, the BesTrade DeAI Agent acts as a Meta Exchange that intelligently connects users and value by optimizing transaction pathways and returns. Following the beta release, a global user growth campaign will begin — positioning BesTrade as a top-tier AI trading platform and the second engine of the Crypto Flywheel.

3. Launch Crypto Ecosystem Tokens on Leading Exchanges

Supported by a potential C10 stablecoin and EAI + Crypto RWA dual-bridge products, AIxCrypto could build a sustainable on-chain value growth system — serving as the third engine of the Crypto Flywheel.

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a biotechnology company based in Carlsbad, California, specializing in the development and commercialization of innovative oncology and immunology therapies. The company is also actively expanding into crypto asset and Web3 strategies, integrating cutting-edge technology with capital market innovation to accelerate global growth and ecosystem expansion.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company’s forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, including the Company’s ability to file its Form 10-Q for the period ended September 30, 2025, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company’s shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq’s continued listing requirement, or its alternatives, or otherwise in the future, and the other risks set forth in the Company’s filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor & Media Contact:
Investor Relations Department
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300, Carlsbad, CA 92008
Tel: +1 (760) 452-8111
Email: info@qualigeninc.com

FAQ

When will Qualigen (QLGN) officially become AIxCrypto?

The company will rebrand following the stockholder meeting on November 12, 2025.

What is the BesTrade DeAI Agent launch date for QLGN/AIxCrypto?

AIxCrypto plans a public beta of the BesTrade DeAI Agent by the end of November 2025.

How much has QLGN allocated to its C10 Treasury as of October 2025?

As of October 17, 2025, the C10 Treasury completed $12 million in crypto asset allocations.

What 2025 AUM target did AIxCrypto set for the C10 Treasury?

AIxCrypto aims to expand the C10 Treasury to $50 million AUM by the end of 2025.

Will AIxCrypto publish a token whitepaper and when?

The company will release an EAI RWA Utility Token Whitepaper following the rebrand and beta launch timeline in late 2025.

Who is the majority owner of Qualigen (QLGN) ahead of the rebrand?

Qualigen is majority owned by Faraday Future Intelligent Electric (NASDAQ: FFAI).